• Special Issue Topic

    Immunology, Immunopathology and Genomics of SARS-COV-2

    Submission Deadline: June 30, 2022

    Guest Editors

    Dr. Nitin Saksena E-Mail

    Director, OMICS Centre of Excellence at G42 Healthcare, Abu Dhabi Adjunct Professor, Institute of Health and Sport, Victoria University, Footscray, VIC, Australia. Advisor, Beijing Institute of Genomics, Shenzen, China

    Research Keywords: Oncology, virology, neurodegenerative diseases, clinical trials, medical genomics, biomarker development

    Dr. Srinivasa Reddy Bonam E-Mail

    Institut National de la Santé et de la Recherche Médicale (INSERM); Centre de Recherche des Cordeliers (CRC), Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Université de Paris, Paris F-75006, France

    Research Keywords: Innate immunity, adaptive immunity, vaccine development, T-cell immunology, antigen presentation, immunomodulation, cytokines, phytochemicals

    Dr. Thyago Cardoso  E-Mail

    Research and Development Scientist, OMICS Center of Excellence, G42 Healthcare, Masdar city, Abu Dhabi. UAE

    Dr. Monica Miranda-Saksena E-Mail

    Senior Research Fellow Medicine, Westmead Clinical School, The Westmead Institute for Medical Research

    About the Special Issue

    Exploration of Immunology is creating a special issue on the "Current immunological perspectives in SARS-CoV-2" to clarify critical immunological issues and bridge the gaps where there is a lack of understanding encompassing immune responses to the virus to vaccination. The topic is very keen in proving a wide-coverage and a much-needed understanding on immunology and immunopathology of SARS-CoV-2. Editors of this special issue are interested in welcoming the submission of Original Research articles, short research reports covering novel findings, Reviews(both long and short), which include, but are not limited to:

    •Correlates of immune protection during SARS-CoV-2

    This is a broader category and the articles providing discussion on correlates of immune protection in unvaccinated individuals, vaccinated individuals and also in critically ill patients with SARS-CoV-2 form the backbone of this section. In addition, articles providing factual discussion on cell-mediated immunity, humoral immunity, innate and adaptive immunity during the infection and also in vaccinated individuals will be ideal to unite the themes for a holistic understanding. 

    •Development & Validation of SARS-CoV-2 immunological Screening for diagnostics 

    We are looking for the consolidation of novel immunological testing strategies and diagnostic methods that have benefited the patients in detecting their immune responses during the pandemic and what more can be done in this area in addition to discussing the novel methods in the pipeline. A focused discussion on new technologies is highly welcome.

    •Immunopathology of SARS-CoV-2

    This section will welcome articles that highlight and discuss critical issues in pathology with a wider coverage on lung pathology, heart pathology, neuropathology, in addition to immunopathology and its role in mild, moderate and severe disease with SARS-CoV-2. Immune evasion will be one of the most welcome addition to the topic.

    •Genomic basis of SARS-CoV-2 infection and immune evasion from vaccine responses 

    There is paucity of information in this area of research and it will be ideal if a genomic basis of SARS-CoV-2 infection can be summarized with what is currently known, in addition to highlighting immune evasion as a result of viral mutations and their implications in disease pathogenesis and vaccine efficacy. 

    •Therapeutics and Vaccine Studies 

    Here, in this section, it is expected to cover the vaccine strategies utilized in immunization against SARS-CoV-2 infection and the outcomes with these diverse vaccines. Also, it is expected to highlight novel vaccines with improved design for the future.

    Keywords: COVID-19 immunology, immunopathology, genomics of SARS-CoV-2, vaccines, cellular immune responses, diagnostic technologies for SARS-CoV-2

    Call for Papers

    Published Articles

    Open Access
    The immune response of nano carbon-based photic-driving vaccines to severe acute respiratory syndrome coronavirus 2
    As the most severe novel infectious disease in this century, coronavirus disease 2019 (COVID-19) faces tremendous challenges due to the hysteresis of drugs and vaccine development. Elucidating the p [...] Read more.
    Junming Chen ... Jianshe Yang
    Published: May 17, 2024 Explor Immunol. 2024;4:325–332
    DOI: https://doi.org/10.37349/ei.2024.00143
    Times Cited: 0
    Open Access
    COVID-19 induced ARDS: immunopathology and therapeutics
    The coronavirus disease-2019 (COVID-19) pandemic is a significant threat in the modern era. Clinical studies show that the most common symptom of severe COVID-19 is viral pneumonia-induced acute res [...] Read more.
    Sneha Das ... Rupesh K. Srivastava
    Published: August 04, 2023 Explor Immunol. 2023;3:255–275
    DOI: https://doi.org/10.37349/ei.2023.00101
    Times Cited: 0
    Open Access
    Innate immune cell and severe acute respiratory syndrome coronavirus 2 interaction
    Coronavirus disease caused by the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a major public health that has submerged the world into a crisis unpreceden [...] Read more.
    Naima G. Cortes-Perez
    Published: February 26, 2023 Explor Immunol. 2023;3:28–39
    DOI: https://doi.org/10.37349/ei.2023.00087
    Times Cited: 0
    Open Access
    Incursions by severe acute respiratory syndrome coronavirus-2 on the host anti-viral immunity during mild, moderate, and severe coronavirus disease 2019 disease
    The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the human host can lead to various clinical manifestations, from symptomless carriers to mild to moderate to severe/critical illness. Therefore, the cli [...] Read more.
    Nitin Saksena ... Thyago H. Cardoso
    Published: December 29, 2022 Explor Immunol. 2022;2:794–811
    DOI: https://doi.org/10.37349/ei.2022.00084